(Total Views: 490)
Posted On: 04/07/2021 1:15:56 PM
Post# of 154090
I was surprised to see all of those biomarkers in the LH protocol but very happy they are there because in the CD12 there was no monitoring of biomarkers that I saw in that protocol.
Then when we got the CD12 numbers I was suspicious that some of the patients weren't even given their LL. I was a little reassured when we saw the 14 day numbers.
I do want to see some testing of biomarkers in any CD16 or CD17 trials. At least RO levels. I want verification patients were getting their LL.
The results for CD12 that we saw in the 8-K was an executive summary. I can't imagine that the FDA would not want a Top Line report of the trial, especially if Cytodyn wants them to act on CD12 numbers.
Someone on the Yahoo board said Amarex was still crunching number until the end of March. Is that a possibility? I would like to ask Cytodyn about the Top Line report but it doesn't seem my questions ever get asked.
Have any insights on these issues?
Then when we got the CD12 numbers I was suspicious that some of the patients weren't even given their LL. I was a little reassured when we saw the 14 day numbers.
I do want to see some testing of biomarkers in any CD16 or CD17 trials. At least RO levels. I want verification patients were getting their LL.
The results for CD12 that we saw in the 8-K was an executive summary. I can't imagine that the FDA would not want a Top Line report of the trial, especially if Cytodyn wants them to act on CD12 numbers.
Someone on the Yahoo board said Amarex was still crunching number until the end of March. Is that a possibility? I would like to ask Cytodyn about the Top Line report but it doesn't seem my questions ever get asked.
Have any insights on these issues?
(1)
(0)
